Drug Trial Radar · NCT07109284
SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer
Last checked: Nov 19, 2026Latest source record: Aug 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
55
Planned (sponsor's estimate)
Start
Sep 2025
Primary completion
Jan 2028
Study completion Dec 2030
Sponsor
- Lead sponsor
- West China HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aimed to evaluate the efficacy and safety of SKB264 combined with KL-A167 as neoadjuvant therapy in early-stage high-risk ER+HER2- breast cancer patients.
Conditions
- ER+HER2- Breast Cancer
Interventions
Sacituzumab tirumotecanBiological
Sacituzumab tirumotecan 5 mg/kg, intravenously (iv), Q2W
TagitanlimabBiological
Tagitanlimab 900mg, intravenously (iv), Q2W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pathological Complete Response (pCR) Rate (ypT0/Tis ypN0)Time frame: Up to approximately 6 months (Time of surgery)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.